The DOI matches its OpenAlex record.
A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis
Abstract
Background: To study the relation between reported drug performance in published trials and support of the trials by the manufacturer of the drug under evaluation, we studied a sample of trials of nonsteroidal anti-inflammatory drugs (NSAIDs) used in the treatment of arthritis. Methods: All randomized control trials of NSAIDs published between September 1987 and May 1990 identified by MEDLINE were reviewed. If an article met the following criteria (n=61), it was selected: trials involving adult patients with osteoarthritis or rheumatoid arthritis (n=180), use of nonsalicylate NSAIDs marketed in the United States (n=101), randomized control trial (n=81), duration of the trial 4 or more days (n=78), and use of an efficacy outcome measure (n=61). Reviewers, "blinded" to manufacturer status, evaluated the narrative interpretation of results and extracted numeric data on efficacy and toxicity. Manufacturer-associated trials were defined as those that acknowledged an association with a pharmaceutical manufacturer. Because of the scarcity of non—manufacturer-associated trials (n=9), we report only on the manufacturer-associated articles. Results: Fifty-two publications (85.2%) representing 56 trials were associated with a manufacturer. The manufacturer-associated drug was reported as comparable with (71.4%) or superior to (28.6%) the comparison drug in all 56 trials. These narrative claims of superiority were usually justified with trial data. Of the trials identifying one drug as less toxic (n=22), the manufacturer-associated drug's safety was reported as superior to the comparison drug in 86.4% of cases. Justification for the narrative interpretation of the trial findings regarding less toxicity was provided in only 12(54.5%) of 22 trials. Conclusion: The manufacturer-associated NSAID is almost always reported as being equal or superior in efficacy and toxicity to the comparison drug. These claims of superiority, especially in regard to side effect profiles, are often not supported by trial data. These data raise concerns about selective publication or biased interpretation of results in manufacturer-associated trials. (Arch Intern Med. 1994;154:157-163)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Systematic Review and Meta-analysis: When One Study Is Just not Enough
Garg, A. X., Hackam, D., & Tonelli, M. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01430307 · Cited by 2,258
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?
Wazana, A. (2000) · JAMA · doi:10.1001/jama.283.3.373 · Cited by 1,415
meta-analysis bias in location and selection of studies
Egger, M., & Smith, G. D. (1998) · BMJ · doi:10.1136/bmj.316.7124.61 · Cited by 1,374
Uneasy alliance—clinical investigators and the pharmaceutical industry
Bodenheimer, T. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422024 · Cited by 765
Als-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746
Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry
Choudhry, N. K. (2002) · JAMA · doi:10.1001/jama.287.5.612 · Cited by 646
Coverage by the news media of the benefits and risks of medications
Moynihan, R., Bero, L., Ross-Degnan, D., Henry, D., Lee, K., Watkins, J., Mah, C., & Soumerai, S. B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006013422206 · Cited by 500
Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies
Smith, R. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020138 · Cited by 498
The uncertainty principle and industry-sponsored research
Djulbegovic, B., Lacevic, M., Cantor, A., Fields, K. K., Bennett, C. L., Adams, J. R., Kuderer, N. M., & Lyman, G. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02605-2 · Cited by 482
Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology
Friedberg, M. (1999) · JAMA · doi:10.1001/jama.282.15.1453 · Cited by 477
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
Kemmeren, J. M., Algra, A., & Grobbee, D. E. (2001) · BMJ · doi:10.1136/bmj.323.7305.131 · Cited by 455
Jørgensen, A. W., Hilden, J., & Gøtzsche, P. C. (2006) · BMJ · doi:10.1136/bmj.38973.444699.0b · Cited by 444
Why review articles on the health effects of passive smoking reach different conclusions
Barnes, D. E. (1998) · JAMA · doi:10.1001/jama.279.19.1566 · Cited by 442
Publication and related biases.
Song, Eastwood, Gilbody, Duley, & Sutton (2000) · Health Technology Assessment · doi:10.3310/hta4100 · Cited by 427
Relation between agendas of the research community and the research consumer
Tallon, D., Chard, J., & Dieppe, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02351-5 · Cited by 416
Factors that limit the quality, number and progress of randomised controlled trials
Prescott, Counsell, Gillespie, Grant, Russell, Kiauka, Colthart, Ross, Shepherd, & Russell (1999) · Health Technology Assessment · doi:10.3310/hta3200 · Cited by 390
Rising, K., Bacchetti, P., & Bero, L. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050217 · Cited by 328
Factors Associated With Failure to Publish Large Randomized Trials Presented at an Oncology Meeting
Krzyzanowska, M. K. (2003) · JAMA · doi:10.1001/jama.290.4.495 · Cited by 314
Pharmaceutical company funding and its consequences: A qualitative systematic review
Sismondo, S. (2008) · Contemporary Clinical Trials · doi:10.1016/j.cct.2007.08.001 · Cited by 304
Ridker, P. M., & Torres, J. (2006) · JAMA · doi:10.1001/jama.295.19.2270 · Cited by 303
The Contract Research Organization and the Commercialization of Scientific Research
Mirowski, P., & Van Horn, R. (2005) · Social Studies of Science · doi:10.1177/0306312705052103 · Cited by 260
Relationship between conflicts of interest and research results
Friedman, L. S., & Richter, E. D. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30617.x · Cited by 258
Bero, L., Oostvogel, F., Bacchetti, P., & Lee, K. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040184 · Cited by 249
DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS
SAFER, D. J. (2002) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200209000-00002 · Cited by 180
Barnes, D. E., & Bero, L. A. (1996) · Journal of Health Politics, Policy and Law · doi:10.1215/03616878-21-3-515 · Cited by 176
Industry sponsorship and research outcome: systematic review with meta-analysis
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5293-7 · Cited by 162
The Price of Truth: How Money Affects the Norms of Science
Resnik, D. B. (2007) · doi:10.1093/acprof:oso/9780195309782.001.0001 · Cited by 160
Industry support and correlation to study outcome for papers published in Spine
Shah, R. V., Albert, T. J., Bruegel-Sanchez, V., Vaccaro, A. R., Hilibrand, A. S., & Grauer, J. N. (2005) · Spine · doi:10.1097/01.brs.0000161004.15308.b4 · Cited by 155
Tham, A., Jonsson, U., Andersson, G., Söderlund, A., Allard, P., & Bertilsson, G. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.06.013 · Cited by 104
Altwairgi, A. K., Booth, C. M., Hopman, W. M., & Baetz, T. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8319 · Cited by 43
Metadata
- Authors
- Rochon, P. A.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association
- Published
- 1994-01-24
- Volume
- 154
- Issue
- 2
- Pages
- 157-163
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W4240442341
- Cited by
- 274
- References
- 0
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.